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Summary. The epidermal growth factor receptor 
(EGFR) plays a crucial role in growth, differentiation 
and motility of normal as well as tumor cells. The 
transduction of extracellular signals to the cytoplasm via 
the receptor not only depends on ligand binding, but is 
also determined by the receptor density on the cell 
surface. Therefore, in terms of cancer diagnosis and 
therapeutic approaches targeting EGFR it is decisive to 
know how the expression level of EGFR is controlled. 
We found that transcription activity declines with 
increasing numbers of CA dinucleotides of a highly 
polymorphic CA repeat in the first intron epidermal 
growth factor receptor gene. In vivo data from cultured 
cell l ines support these findings, although other 
regulation mechanisms can compensate this effect. In 
addition, we showed that RNA elongation terminates at 
a site closely downstream of the simple sequence repeat 
(SSR) and that there are two separate major transcription 
start sites. Model calculations for the helical DNA 
conformation revealed a high bendability in the EGFR 
polymorphic region, especially if the CA stretch is 
extended. These data suggest that the CA-SSR can act 
like a joint bringing the promoter in proximity to a 
putative repressor protein bound downstream of the CA- 
SSR. The data suggest that this polymorphism is a 
marker for cancer linking genetic and epigenetic risk. 
Furthermore in breast cancer, heterozygous tumours with 
short CA-SSR showed an elevated EGFR-expression in 
contrast to tumours with longer CA-SSR. Tumours with 
loss of heterozygosity in intron 1 of egfr revealed an 
increased EGFR expression if the longer allele was lost. 
Moreover, deceased egfr gene dosages were significantly 
correlated to poor prognosis in breast cancer. 
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The ERBB gene family 
The c-erbB family of proto-oncogenes plays an 
important role in cell growth, differentiation and motility 
of normal as well as tumour cells. The transduction of 
extracellular signals to the cytoplasm via c-erbB 
receptors does not only depend on the ligands binding to 
the extracellular domain, but is also determined by 
concentrations of the different receptors on the cell 
surface. Therefore, it is crucial to know how the 
expression levels of c-erbB genes are controlled. Besides 
post-translational mechanisms, alteration of gene copy 
numbers or of mRNA levels are two major ways in 
which the expression of genes can be regulated. 
The v-erbB oncogene is carried by the retroviruses 
ALV (avian leukosjs virus), ASV (avian sarcoma virus), 
and AEV (avian erythroblastosis virus). In the AEV-ES4 
strain, it is accompanied by the v-erbA gene (Rothe 
Meyer and Engelbreth-Holm, 1933). The two genes are 
functionally not related. The v-erbA product is a high 
affinity receptor for the thyroid hormone triiodo- 
thyronine (T3) while v-erbB codes for a 68  kDa 
glycoprotein with constitutive tyrosine kinase activity. v- 
erbB causes rapid induction of erythroblastosis and 
sarcomas after intramuscular injection of the carrying 
virus (Hesketh, 1994).  The  first human cellular 
homologue of the v-erbB gene to be identified was the 
epidermal growth factor receptor (egfrlc-erbB-l) gene. 
The  viral oncoprotein is  almost identical to  the 
transmembrane and cytoplasmatic domain of EGFR. 
Unlike v-erbB, EGFR carries an extracellular domain 
and is activated after ligand binding. It was initially 
localized to chromosome 7p13-q22 (Kondo and 
Shimizu, 1983) and later mapped more precisely to p13- 
p12. The egfr locus covers 110 kbp and 26 exons (Maley 
et al., 1987). The cDNA consists of 3630 bp (Ullrich et 
al., 1984). To date, three other members of the erbB 
family of tyrosine kinase receptors have been identified: 
c-erbB-2 (HER-2/neu), c-erbB-3 (HER-3), and c-erbB-4 
(HER-4). They all share broad homologies with egfrlc- 
erbB-l. Before the human c-erbB-2 proto-oncogene was 







